IP Verse

Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes - EP3517539

The patent EP3517539 was granted to Boehringer Ingelheim on Dec 14, 2022. The application was originally filed on Jul 13, 2012 under application number EP19151416A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3517539

BOEHRINGER INGELHEIM
Application Number
EP19151416A
Filing Date
Jul 13, 2012
Status
Granted And Under Opposition
Nov 11, 2022
Grant Date
Dec 14, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPSep 14, 2023HAMM & WITTKOPPADMISSIBLE
KNPP PARTGMBBSep 14, 2023DR VOLGERADMISSIBLE
KNPP PARTGMBBSep 14, 2023VOLGERADMISSIBLE
MAIWALDSep 13, 2023MAIWALDADMISSIBLE

Patent Citations (33) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0564409
DESCRIPTIONUS5093330
DESCRIPTIONWO2004005281
DESCRIPTIONWO2004018468
DESCRIPTIONWO2004050658
DESCRIPTIONWO2005085246
DESCRIPTIONWO2006029769
DESCRIPTIONWO2006041976
DESCRIPTIONWO2006048427
DESCRIPTIONWO2007005572
DESCRIPTIONWO2007071738
DESCRIPTIONWO2008017670
DESCRIPTIONWO2012088682
DESCRIPTIONWO2012089127
DESCRIPTIONWO9835958
OPPOSITIONCN104130258
OPPOSITIONEP2023902
OPPOSITIONUS2006142310
OPPOSITIONUS7407955
OPPOSITIONWO2004018468
OPPOSITIONWO2010072776
OTHERCN104130258
OTHEREP2731947
OTHERUS2004097510
OTHERUS7407955
OTHERWO2013010964
SEARCHDE102004044221
SEARCHDE102004054054
SEARCHUS2004097510
SEARCHWO2004018468
SEARCHWO2004050658
SEARCHWO2005085246
SEARCHWO2008017670

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALLINGER N. L.; ELIEL E. L., Topics in Stereochemistry, Wiley Interscience, (19710000), vol. 6-
OPPOSITION- Anonymous, "Final report for project 15232 . Results of experiments of Linagliptin", TAROS Chemicals, (20210318), pages 1 - 3, TAROS Chemicals, (20231220), XP093113887-
OPPOSITION- Anonymous, "Linagliptin methyl dimer safety datasheet", TLC PHARMACEUTICAL STANDARDS, (20191204), pages 1 - 4, TLC PHARMACEUTICAL STANDARDS, URL: https://static.cymitquimica.com/products/4Z/pdf/sds-L-445.pdf, (20231220), XP093113886-
OPPOSITION- Ben Adams, "Publication Pharmafile: Boehringer-Lilly launch diabetes drug Tradjenta", Pharmafile, (20110616), Pharmafile, URL: http://www.pharmafile.com/print/159891, (20191211), XP055651961-
OPPOSITION- BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. et al., Boehringer Ingelheim and Lilly's New Type 2 Diabetes Treatment Tradjenta(TM) Linagliptin Tablets For Adults Now Available in U.S. Pharmacies, (20110615), XP055651947-
OPPOSITION- Emea, "ICH Topic Q 3 A (R2) Impurities in new Drug Substances ICH Step 5 NOTE FOR GUIDANCE ON IMPURITIES TESTING: IMPURITIES IN NEW DRUG SUBSTANCES", EMEA CPMP/ICH/2737/99, (20061001), pages 1 - 15, EMEA CPMP/ICH/2737/99, (20231220), XP093113891-
OPPOSITION- Fda, "Initial Quality/CMC Assessment ONDQA: Linagliptin", FDA - Drug Approval Package, (20110502), FDA - Drug Approval Package, (20231220), XP093113889-
OPPOSITION- Fda, "Tradjenta (Linagliptin) Tablets", FDA - Drug Approval Package, (20110607), FDA - Drug Approval Package, (20231220), XP093113890-
OPPOSITION- Fda, "Tradjenta® (linagliptin) tablets", Highlights prescribing information, (20110501), Highlights prescribing information, (20231220), XP093113888-
OPPOSITION- results of experiments conducted by an anonymous laboratory-
OPPOSITION- Jeffery B Press, Bandurco Victor T, Wong Elizabeth M, Hajos Zoltan G, Kanojia Ramesh M, Malloryt Robert A, Deegan Edward G, Mcnally James J, Roberts Jerry R, Cotter Mary Lou, Graden David W, Lloyd John R, "Synthesis of 5,6-Dimethoxyquinazolin-2(1H)-ones", Journal of Heterocyclic Chemistry, (19860424), vol. 23, no. 6, doi:10.1002/jhet.5570230643, pages 1821 - 1828, XP055650667
OPPOSITION- ECKHARDT MATTHIAS ET AL, "8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quina zolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes", Journal of Medicinal Chemistry, US , (20071201), vol. 50, no. 26, doi:10.1021/jm701280z, ISSN 0022-2623, pages 6450 - 6453, XP002495244
OPPOSITION- Matthias Eckhardt , Elke Langkopf, Michael Mark, Moh Tadayyon, Leo Thomas, Herbert Nar, Waldemar Pfrengle, Brian Guth, Ralf Lotz, Peter Sieger, Holger Fuchs, Frank Himmelsbach, "8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quina zolin- 2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20071227), vol. 50, no. 26, doi:10.1021/jm701280z, ISSN 0022-2623, pages 6450 - 6453 + S1 - S18, XP002576167
OPPOSITION- Jiben Roy, "Pharmaceutical impurities—A mini-review", AAPS PharmSciTech, (20020601), vol. 3, no. 2, doi:10.1208/pt030206, pages 1 - 8, XP055650671

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents